4//SEC Filing
Aghazadeh Behzad 4
Accession 0001104659-20-075724
CIK 0000722830other
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 6:42 PM ET
Size
12.3 KB
Accession
0001104659-20-075724
Insider Transaction Report
Form 4
IMMUNOMEDICS INCIMMU
Avoro Capital Advisors LLC
Director
Transactions
- Award
Common Stock, $0.01 par value per share (''Common Stock'')
2020-06-18+3,718→ 17,234 total - Award
Stock Option (right to buy)
2020-06-18+6,540→ 6,540 totalExercise: $33.62From: 2021-06-18Exp: 2030-06-18→ Common Stock, par value $0.01 per share (6,540 underlying)
Holdings
- 26,250,000(indirect: See footnotes)
Common Stock
- 100,000
Common Stock
Aghazadeh Behzad
Director10% OwnerOther
Transactions
- Award
Common Stock, $0.01 par value per share (''Common Stock'')
2020-06-18+3,718→ 17,234 total - Award
Stock Option (right to buy)
2020-06-18+6,540→ 6,540 totalExercise: $33.62From: 2021-06-18Exp: 2030-06-18→ Common Stock, par value $0.01 per share (6,540 underlying)
Holdings
- 100,000
Common Stock
- 26,250,000(indirect: See footnotes)
Common Stock
Footnotes (6)
- [F1]Such securities are held on behalf of accounts managed by Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC (formerly venBio Select Fund LLC), a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
- [F2]The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
- [F3]Such grants of restricted stock units ("RSUs") and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020.
- [F4]Includes RSUs held by Dr. Aghazadeh that represent a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest on the first anniversary of the date of grant, subject to Dr. Aghazadeh's continued service as a director of the Issuer.
- [F5]Includes RSUs held by Dr. Aghazadeh, granted on March 20, 2020. 1/3 of the RSUs vest on each of the first, second and third anniversary of the date of grant, subject to Dr. Aghazadeh's continued service as the Issuer's Executive Chairman.
- [F6]The stock options vest on the first anniversary of the date of grant, subject to Dr. Aghazadeh's continued service as a director of the Issuer.
Documents
Issuer
IMMUNOMEDICS INC
CIK 0000722830
Entity typeother
Related Parties
1- filerCIK 0001701815
Filing Metadata
- Form type
- 4
- Filed
- Jun 21, 8:00 PM ET
- Accepted
- Jun 22, 6:42 PM ET
- Size
- 12.3 KB